Genscript Biotech's (HKG:1548) associate Legend Biotech said CARVYKTI generated net trade sales of around $657 million in the quarter ended June 30, according to a Wednesday Hong Kong bourse filing.
Shares of the life sciences company were down over 2% in Thursday afternoon trading.
The sales have been generated under a license agreement between Legend Biotech and Janssen Biotech, with the sales figure provided by the latter.